OsteoporosisNCT00449215
The Genetic and Life Style Determinants of Bone Mass of Young Greek Males
An observational study of Osteoporosis, run by University of Athens at 1 site in Greece.
Trial summary
The genetic bases of peak bone mass in males, as determinants of an individual's risk of developing osteoporotic fractures in old age and their interaction with dietary and lifestyle factors are still poorly understood. Read more about this study
- Who is it for?
- Ages 16 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Osteoporosis
- How many people
- 301 participants
- Where
- 1 siteGreece
- Study dates
- Oct 2004to Dec 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 35 years
- Men only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Greek healthy young men
Who cannot join
- Men who were treated with corticosteroids, anticonvulsants, or anticoagulants or who suffered from hypogonadism, kidney, liver, thyroid and gastrointestinal disease or diabetes mellitus were excluded from the study.
Trial locations and contacts
1 site in 1 country.
Greece1 site
Laboratory for Research of Musculoskeletal System, University of Athens
Athens, 14561
About this study
The genetic bases of peak bone mass in males, as determinants of an individual's risk of developing osteoporotic fractures in old age and their interaction with dietary and lifestyle factors are still poorly understood.
Our objective was to examine the relative contribution of genetic and environmental variables to the regulation of peak bone mass in a population-based cohort of young healthy men, focusing on the BsmI polymorphism of vitamin D receptor (VDR)gene and the AluI polymorphism of calcitonin receptor (CTR)gene.
Read the detailed description
Material and Methods
Subjects
In this cross-sectional study, 301 Greek healthy young men, aged 16-35 were selected during gradational examinations for the Greek Armed forces. Men who were treated with corticosteroids, anticonvulsants, or anticoagulants or who suffered from hypogonadism, kidney, liver, thyroid and gastrointestinal disease or diabetes mellitus were excluded from the study.
Approval by the hospital ethics committee and informed consent were obtained. Height and body weight were measured with the subjects in sportswear, standing barefoot on a fixed stadiometer and on a standard clinical balance. Height was recorded in centimetres and weight in kilograms. The stadiometer and scale were routinely monitored for accuracy and precision. Body mass index (BMI) was calculated as weight/height 2 .
Dietary Evaluation
Current dietary factors (calcium, proteins, alcohol, coffee and tea intake), were assessed using a food frequency questionnaire validated in the MEDOS study, and completed with an interview. Calcium intake was estimated considering milk, yogurt and cheese consumption. Protein intake was estimated by taking into account the consumption of meat and fish per week. Tea and coffee consumption was also taken into account.
Nondieter factors were investigated using a questionnaire
Physical was quantified as hours of sports activities per week (defined as taking part in organized sport for at least 12 months). Smoking behaviour was coded as 'yes' (daily smoking) or 'no', and sunlight exposure when there was exposure in places abroad during the previous 3 months. Duration of immobilizations was also coded as 'less' or 'more than 1 month' (in majority, due to fractures caused by high energy trauma).
Genetic analyses
Genomic DNA was extracted from peripheral blood leukocytes with a DNA extraction kit (Puregene DNA isolation kit, Gentra Systems Inc., Munich, Germany). Polymorphisms in the CTR and VDR genes were determined by polymerase chain reaction (PCR) as previously described using Taq DNA polymerase (Takara, Tokyo, Japan), and thermal cycler (PCR Primus 96 plus-MWG AG BIOTECH). 4μl of CTR-PCR product were digested with AluI (New England Biolabs, UK) and 2 μl of VDR-PCR product were digested with BsmI (New England Biolabs, UK) according to manufacturer’s instructions. AluI restriction digest yielded DNA fragments of 120/108-bp (TT), 228/120/108-bp (TC) and 228-bp (CC) and BsmI restriction digest yielded DNA fragments of 1200/650-bp (bb), 1850/1200/650-bp (Bb) and 1850-bp (BB), which were visualized using a 3% and 1% agarose gel respectively stained with ethidium bromide.
BMD Measurements
Distal BMC (dBMC), distal BMD (dBMD) and ultradistal BMD (udBMD) at the radius were measured by single X-ray absorptiometry (Osteometer DTX-100, Denmark). Additionally, there were assessments of the corresponding geometrical areas, such as radial area (RadAr), ulnar area (UlnAr) and ultradistal area (udAr). BMD is expressed as grams/cm2; BMC is expressed in grams and Area as cm2 The in vivo precision for the BMD and BMC measurements in our laboratory was 1-5%.
Statistical Analysis
Descriptive statistics were determined for all variables. All variables are sufficiently represented using the mean value (mean) and standard deviation (SD).
Univariate analysis was performed using the two-sample Student's test or Welch-test (in a case of unequal SDs) and the model of one-way analysis of variance with no repeated measurements (pairwise multiple comparisons were analysed using the Tukey test). Analysis of covariance (ANCOVA) used the bone values (BMC, BMD, Area) as dependent variables, the VDR and CTR polymorphisms as factors and age, weight and height as covariates. Furthermore, multiple stepwise regression analysis was used to determine significant predictors of BMD. All tests are two sided; P<0, 05 was defined as significant. All data analysis was performed using the Statistical Package for Social Sciences (version 10.0) software (SPSS Inc., Chicago, IL).
- Conditions
- Osteoporosis
- Keywords
- Peak Bone Mass; Male; Genetic Polymorphisms
- Medical subject headings
- Osteoporosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2007 (estimated)
- Study startOct 2004
- Study completionDec 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for OsteoporosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Other
- Enrolment
- 301 participants
Sponsor and investigators
- Lead sponsor
- University of Athens
- Sponsor type
- University, hospital or other
- Investigators
- Ioannis N Charopoulos, M.D, Principal investigator, Laboratory Of Research Of Musculoskeletal System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00449215
- Sponsor's protocol ID
- AA-88-H-0010
- Status last verified
- Mar 2007
- First submitted
- 18 Mar 2007
- Last updated
- 20 Mar 2007
- Results posted
- No
- Data monitoring committee
- No
Publications
Gunnes M, Berg JP, Halse J, Lehmann EH. Lack of relationship between vitamin D receptor genotype and forearm bone gain in healthy children, adolescents, and young adults. J Clin Endocrinol Metab. 1997 Mar;82(3):851-5. doi: 10.1210/jcem.82.3.3814.
PubMed 9062495
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Genetic and Life Style Determinants of Bone Mass of Young Greek Males
- ClinicalTrials.gov ID
- NCT00449215
- Acronym / sponsor ID
- AA-88-H-0010
- Conditions
- Osteoporosis
- Keywords
- Peak Bone Mass; Male; Genetic Polymorphisms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 301 participants
- Lead sponsor
- University of AthensUniversity, hospital or other
- Study start
- Oct 2004
- Study completion
- Dec 2006 (actual)
- First posted
- 20 Mar 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The genetic bases of peak bone mass in males, as determinants of an individual's risk of developing osteoporotic fractures in old age and their interaction with dietary and lifestyle factors are still poorly understood.
Our objective was to examine the relative contribution of genetic and environmental variables to the regulation of peak bone mass in a population-based cohort of young healthy men, focusing on the BsmI polymorphism of vitamin D receptor (VDR)gene and the AluI polymorphism of calcitonin receptor (CTR)gene.
Detailed description
Material and Methods
Subjects
In this cross-sectional study, 301 Greek healthy young men, aged 16-35 were selected during gradational examinations for the Greek Armed forces. Men who were treated with corticosteroids, anticonvulsants, or anticoagulants or who suffered from hypogonadism, kidney, liver, thyroid and gastrointestinal disease or diabetes mellitus were excluded from the study.
Approval by the hospital ethics committee and informed consent were obtained. Height and body weight were measured with the subjects in sportswear, standing barefoot on a fixed stadiometer and on a standard clinical balance. Height was recorded in centimetres and weight in kilograms. The stadiometer and scale were routinely monitored for accuracy and precision. Body mass index (BMI) was calculated as weight/height 2 .
Dietary Evaluation
Current dietary factors (calcium, proteins, alcohol, coffee and tea intake), were assessed using a food frequency questionnaire validated in the MEDOS study, and completed with an interview. Calcium intake was estimated considering milk, yogurt and cheese consumption. Protein intake was estimated by taking into account the consumption of meat and fish per week. Tea and coffee consumption was also taken into account.
Nondieter factors were investigated using a questionnaire
Physical was quantified as hours of sports activities per week (defined as taking part in organized sport for at least 12 months). Smoking behaviour was coded as 'yes' (daily smoking) or 'no', and sunlight exposure when there was exposure in places abroad during the previous 3 months. Duration of immobilizations was also coded as 'less' or 'more than 1 month' (in majority, due to fractures caused by high energy trauma).
Genetic analyses
Genomic DNA was extracted from peripheral blood leukocytes with a DNA extraction kit (Puregene DNA isolation kit, Gentra Systems Inc., Munich, Germany). Polymorphisms in the CTR and VDR genes were determined by polymerase chain reaction (PCR) as previously described using Taq DNA polymerase (Takara, Tokyo, Japan), and thermal cycler (PCR Primus 96 plus-MWG AG BIOTECH). 4μl of CTR-PCR product were digested with AluI (New England Biolabs, UK) and 2 μl of VDR-PCR product were digested with BsmI (New England Biolabs, UK) according to manufacturer’s instructions. AluI restriction digest yielded DNA fragments of 120/108-bp (TT), 228/120/108-bp (TC) and 228-bp (CC) and BsmI restriction digest yielded DNA fragments of 1200/650-bp (bb), 1850/1200/650-bp (Bb) and 1850-bp (BB), which were visualized using a 3% and 1% agarose gel respectively stained with ethidium bromide.
BMD Measurements
Distal BMC (dBMC), distal BMD (dBMD) and ultradistal BMD (udBMD) at the radius were measured by single X-ray absorptiometry (Osteometer DTX-100, Denmark). Additionally, there were assessments of the corresponding geometrical areas, such as radial area (RadAr), ulnar area (UlnAr) and ultradistal area (udAr). BMD is expressed as grams/cm2; BMC is expressed in grams and Area as cm2 The in vivo precision for the BMD and BMC measurements in our laboratory was 1-5%.
Statistical Analysis
Descriptive statistics were determined for all variables. All variables are sufficiently represented using the mean value (mean) and standard deviation (SD).
Univariate analysis was performed using the two-sample Student's test or Welch-test (in a case of unequal SDs) and the model of one-way analysis of variance with no repeated measurements (pairwise multiple comparisons were analysed using the Tukey test). Analysis of covariance (ANCOVA) used the bone values (BMC, BMD, Area) as dependent variables, the VDR and CTR polymorphisms as factors and age, weight and height as covariates. Furthermore, multiple stepwise regression analysis was used to determine significant predictors of BMD. All tests are two sided; P<0, 05 was defined as significant. All data analysis was performed using the Statistical Package for Social Sciences (version 10.0) software (SPSS Inc., Chicago, IL).
Study design
- Observational model
- Defined population
- Time perspective
- Other
Who may qualify
- Ages
- 16 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Greek healthy young men
Key exclusion criteria (1 listed)
- Men who were treated with corticosteroids, anticonvulsants, or anticoagulants or who suffered from hypogonadism, kidney, liver, thyroid and gastrointestinal disease or diabetes mellitus were excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2007.
- Background: PubMed 9062495Gunnes M, Berg JP, Halse J, Lehmann EH. Lack of relationship between vitamin D receptor genotype and forearm bone gain in healthy children, adolescents, and young adults. J Clin Endocrinol Metab. 1997 Mar;82(3):851-5. doi: 10.1210/jcem.82.3.3814.
- International Osteoporosis FoundationLink provided by the sponsor.
Related trials for Osteoporosis
RecruitingObservational study
A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.
Vertebra Compression Fracture
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
Not yet recruitingPhase 4
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Postmenopausal Osteoporosis
RecruitingObservational study
Assessment and Comparison of Osteoporosis Risk Factors After Stroke
Stroke, Osteoporosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ioannis N Charopoulos, M.D principal investigator
Laboratory Of Research Of Musculoskeletal System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Osteoporosis, run by University of Athens at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00449215, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2007.